Limitations and strengths
inflammation, AKI septic
INFLAMMATION
Our results must be interpreted with caution, as this was a single-center study without an The strengths of the study lie in its design and the adequate adherence of the patient groups to treatment; to our knowledge, this is the first randomized control trial of AKI septic patients treated with probiotics [In the next study regarding this topic, we suggest measuring the microbiome between groups to quantify an actual difference between those administered the probiotics vs placebo, measure inflammatory markers given the speculation around inflammation and immune regulation. Lastly, a larger and multicenter trial.